These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 11523724)

  • 1. Clinical pharmacokinetics of sirolimus.
    Mahalati K; Kahan BD
    Clin Pharmacokinet; 2001; 40(8):573-85. PubMed ID: 11523724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of everolimus.
    Kirchner GI; Meier-Wiedenbach I; Manns MP
    Clin Pharmacokinet; 2004; 43(2):83-95. PubMed ID: 14748618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirolimus: the evidence for clinical pharmacokinetic monitoring.
    Stenton SB; Partovi N; Ensom MH
    Clin Pharmacokinet; 2005; 44(8):769-86. PubMed ID: 16029064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus.
    MacDonald A; Scarola J; Burke JT; Zimmerman JJ
    Clin Ther; 2000; 22 Suppl B():B101-121. PubMed ID: 10823378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity.
    Kahan BD; Napoli KL; Kelly PA; Podbielski J; Hussein I; Urbauer DL; Katz SH; Van Buren CT
    Clin Transplant; 2000 Apr; 14(2):97-109. PubMed ID: 10770413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients.
    Le Meur Y; Djebli N; Szelag JC; Hoizey G; Toupance O; Rérolle JP; Marquet P
    Clin Pharmacol Ther; 2006 Jul; 80(1):51-60. PubMed ID: 16815317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and metabolism of sirolimus.
    Gallant-Haidner HL; Trepanier DJ; Freitag DG; Yatscoff RW
    Ther Drug Monit; 2000 Feb; 22(1):31-5. PubMed ID: 10688254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD.
    Kirchner GI; Winkler M; Mueller L; Vidal C; Jacobsen W; Franzke A; Wagner S; Blick S; Manns MP; Sewing KF
    Br J Clin Pharmacol; 2000 Nov; 50(5):449-54. PubMed ID: 11069439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients.
    Schädeli F; Marti HP; Frey FJ; Uehlinger DE
    Clin Pharmacokinet; 2002; 41(1):59-69. PubMed ID: 11825097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of sirolimus metabolites in pediatric solid organ transplant recipients.
    Filler G; Bendrick-Peart J; Strom T; Zhang YL; Johnson G; Christians U
    Pediatr Transplant; 2009 Feb; 13(1):44-53. PubMed ID: 18482220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients.
    Djebli N; Rousseau A; Hoizey G; Rerolle JP; Toupance O; Le Meur Y; Marquet P
    Clin Pharmacokinet; 2006; 45(11):1135-48. PubMed ID: 17048977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients.
    Oellerich M; Armstrong VW; Streit F; Weber L; Tönshoff B
    Clin Biochem; 2004 Jun; 37(6):424-8. PubMed ID: 15183289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
    Kovarik JM; Kahan BD; Kaplan B; Lorber M; Winkler M; Rouilly M; Gerbeau C; Cambon N; Boger R; Rordorf C;
    Clin Pharmacol Ther; 2001 Jan; 69(1):48-56. PubMed ID: 11180038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review: metabolism of immunosuppressant drugs.
    Kelly P; Kahan BD
    Curr Drug Metab; 2002 Jun; 3(3):275-87. PubMed ID: 12083321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological surrogates of allograft outcome.
    Mahalati K; Kahan BD
    Ann Transplant; 2000; 5(2):14-23. PubMed ID: 11217202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics of cyclosporin.
    Ptachcinski RJ; Venkataramanan R; Burckart GJ
    Clin Pharmacokinet; 1986; 11(2):107-32. PubMed ID: 3514043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and metabolic disposition of sirolimus in healthy male volunteers after a single oral dose.
    Leung LY; Lim HK; Abell MW; Zimmerman JJ
    Ther Drug Monit; 2006 Feb; 28(1):51-61. PubMed ID: 16418694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic monitoring of sirolimus in human whole-blood samples by high-performance liquid chromatography.
    Maleki S; Graves S; Becker S; Horwatt R; Hicks D; Stroshane RM; Kincaid H
    Clin Ther; 2000; 22 Suppl B():B25-37. PubMed ID: 10823371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.